Quantitative measurement of L1 human papillomavirus type 16 methylation for the prediction of preinvasive and invasive cervical disease

Journal of Infectious Diseases

Volumn 215, Issue 5, 2017, Pages 764-771

  Kottaridi, Christine ^a   Kyrgiou, Maria ^b,c   Pouliakis, Abraham ^a   Magkana, Maria ^a   Aga, Evangelia ^a   Spathis, Aris ^a   Mitra, Anita ^b,c   Makris, George ^a   Chrelias, Charalampos ^a   Mpakou, Vassiliki ^a   Paraskevaidis, Evangelos ^d   Panayiotides, John G ^a   Karakitsos, Petros ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cervical intraepithelial neoplasia; CIN; HPV L1 gene methylation; Human Papillomavirus; Pyrosequencing

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATIONAL STUDY; CPG ISLAND; DISEASE SEVERITY; DNA METHYLATION; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; L1 GENE; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS GENE; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHEMISTRY; CLINICAL TRIAL; GENETICS; GREECE; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; STATISTICAL MODEL; UNITED KINGDOM; UTERINE CERVICAL DISEASES; VIROLOGY; YOUNG ADULT;

CAPSID PROTEIN; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOPROTEIN; VIRUS DNA;

ADULT; AGED; CAPSID PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CPG ISLANDS; DNA METHYLATION; DNA, VIRAL; FEMALE; GENOTYPE; GREECE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LINEAR MODELS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; UTERINE CERVICAL DISEASES; YOUNG ADULT;

EID: 85019781393     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw645     Document Type: Article

References (45)

1. Saslow D, Solomon D, Lawson HW, et al; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 137:516-42
2. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318:904-8
3. Koliopoulos G, Sotiriadis A, Kyrgiou M, Martin-Hirsch P, Makrydimas G, Paraskevaidis E. Conservative surgical methods for FIGO stage IA2 squamous cervical carcinoma and their role in preserving women's fertility. Gynecol Oncol 2004; 93:469-73
4. Kyrgiou M, Pouliakis A, Panayiotides JG, et al. Personalised management of women with cervical abnormalities using a clinical decision support scoring system. Gynecol Oncol 2016; 141:29-35
5. Nasioutziki M, Daniilidis A, Dinas K, et al. The evaluation of p16INK4a immunoexpression/ immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int J Gynecol Cancer 2011; 21:79-85
6. Tsoumpou I, Valasoulis G, Founta C, et al. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study. Gynecol Oncol 2011; 121:49-53
7. Gustinucci D, Giorgi Rossi P, Cesarini E, et al. Use of cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the management of human papillomavirus (HPV)-positive women in cervical cancer screening. Am J Clin Pathol 2016; 145:35-45
8. Gage JC, Hunt WC, Schiffman M, et al; New Mexico HPV Pap Registry Steering Committee. Risk stratification using human papillomavirus testing among women with equivocally abnormal cytology: results from a state-wide surveillance program. Cancer Epidemiol Biomarkers Prev 2016; 25:36-42
9. Fernandez AF, Rosales C, Lopez-Nieva P, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 2009; 19:438-51
10. Mirabello L, Sun C, Ghosh A, et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012; 104:556-65
11. Brandsma JL, Sun Y, Lizardi PM, et al. Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology 2009; 389:100-7
12. Piyathilake CJ, Macaluso M, Alvarez RD, et al. A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia. Cancer 2011; 117:957-63
13. Hublarova P, Hrstka R, Rotterova P, et al. Prediction of human papillomavirus 16 e6 gene expression and cervical intraepithelial neoplasia progression by methylation status. Int J Gynecol Cancer 2009; 19:321-5
14. Mirabello L, Schiffman M, Ghosh A, et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2013; 132:1412-22
15. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114-9
16. Awady MK, Kaplan JB, O'Brien SJ, Burk RD. Molecular analysis of integrated human papillomavirus 16 sequences in the cervical cancer cell line SiHa. Virology 1987; 159:389-98
17. Huang N. Paper 1760-2014: scenarios where utilizing a spline model in developing a regression model is appropriate. http://support.sas.com/resources/papers/ proceedings14/1760-2014.pdf. Accessed 28 June 2016
18. Shin S, Coulter B. Paper SP09-2009: ROC analysis for the evaluation of continuous biomarkers: existing tools and new features in SAS 9.2 http://pharmasug.org/ download/papers/SP09.pdf. Accessed 28 June 2016
19. Varlatzidou A, Pouliakis A, Stamataki M, et al. Cascaded learning vector quantizer neural networks for the discrimination of thyroid lesions. Anal Quant Cytol Histol 2011; 33:323-34
20. Pouliakis A, Margari C, Margari N, et al. Using classification and regression trees, liquid-based cytology and nuclear morphometry for the discrimination of endometrial lesions. Diagn Cytopathol 2014; 42:582-91
21. Zygouris D, Pouliakis A, Margari N, et al. Classification of endometrial lesions by nuclear morphometry features extracted from liquid-based cytology samples: a system based on logistic regression model. Anal Quant Cytopathol Histpathol 2014; 36:189-98
22. Pouliakis A, Margari C, Margari N, et al. Using classification and regression trees, liquid-based cytology and nuclear morphometry for the discrimination of endometrial lesions. Diagn Cytopathol 2014; 42:582-91
23. DiMaggio C. SAS for epidemiologists: applications and methods. New York: Springer, 2013
24. SAS Institute. SAS home page. http://www.sas.com.Accessed on 01 August 2016
25. Xu L, Verdoodt F, Wentzensen N, Bergeron C, Arbyn M. Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer. Cancer Cytopathol 2016; 124:261-72
26. Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev 2013; 3:CD008054
27. Lynge E, Antilla A, Arbyn M, Segnan N, Ronco G. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Eur J Cancer 2009; 45:2714-21
28. Clarke MA, Wentzensen N, Mirabello L, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 2012; 21:2125-37
29. Kalantari M, Garcia-Carranca A, Morales-Vazquez CD, et al. Laser capture microdissection of cervical human papillomavirus infections: copy number of the virus in cancerous and normal tissue and heterogeneous DNA methylation. Virology 2009; 390:261-7
30. Sun C, Reimers LL, Burk RD. Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol 2011; 121:59-63
31. Sun C, McAndrew T, Smith BC, Chen Z, Frimer M, Burk RD. Characterization of HPV DNA methylation of contiguous CpG sites by bisulfite treatment and massively parallel sequencing\-The FRAGMENT approach. Front Genet 2014; 5:150
32. Badal V, Chuang LS, Tan EH, et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol 2003; 77:6227-34
33. Badal S, Badal V, Calleja-Macias IE, et al. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 2004; 324:483-92
34. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28:E32
35. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93:9821-6
36. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques 2002; 33:632, 4, 6-49
37. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007; 2:2265-75
38. Niyazi M, Sui S, Zhu K, Wang L, Jiao Z, Lu P. Correlation between methylation of human papillomavirus-16 L1 gene and cervical carcinoma in Uyghur women. Gynecol Obstet Invest 2016; 82:22-29
39. Bryant D, Hibbitts S, Almonte M, Tristram A, Fiander A, Powell N. Human papillomavirus type 16 L1/L2 DNA methylation shows weak association with cervical disease grade in young women. J Clin Virol 2015; 66:66-71
40. Louvanto K, Franco EL, Ramanakumar AV, et al; Biomarkers of Cervical Cancer Risk Study Team. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type. Int J Cancer 2015; 136:E638-45
41. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016; 354:i3633
42. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ 2014; 349:g6192
43. Kyrgiou M, Arbyn M, Martin-Hirsch P, Paraskevaidis E. Increased risk of preterm birth after treatment for CIN. BMJ 2012; 345:e5847
44. Kyrgiou M, Valasoulis G, Stasinou SM, et al. Proportion of cervical excision for cervical intraepithelial neoplasia as a predictor of pregnancy outcomes. Int J Gynaecol Obstet 2015; 128:141-7
45. Founta C, Arbyn M, Valasoulis G, et al. Proportion of excision and cervical healing after large loop excision of the transformation zone for cervical intraepithelial neoplasia. BJOG 2010; 117:1468-74